Investor Suit Against Dendreon Can Proceed
A federal court has allowed an investor class action alleging that Dendreon Corp. and its officers deceived investors about the approval process for its experimental advanced prostate cancer drug Provenge to...To view the full article, register now.
Already a subscriber? Click here to view full article